Skip to main content
  • Login
Home

User account menu

  • Log in

Mega menu

  • EASL
  • Resources

    Resources

    • EASL Resources
      • All Resources
      • Basic Techniques in Experimental Hepatology at a Glance
      • Clinical Practice Guidelines
      • Congress Resources
      • COVID-19 Resources
      • EASL Quiz
      • ePosters
      • Nurses and AHPs
      • On-demand Webinars
      • Webinars
      • Online Courses
      • Podcasts
      • Slide Decks
      • Webcasts
    • Other Resources
      • ERN Rare-Liver On-demand Webinars
      • Baveno VII - Consensus Workshop
      • Baveno VII - Pediatric Research Workshop
    • Industry Resources
      • All Resources
      • Industry Symposia - International Liver Congress
      • Industry Symposia - Digital Liver Cancer Summit 2021
      • Industry Symposia - Liver Cancer Summit 2022
      • Intercept - Primary Biliary Cholangitis: Clinical management
      • Online Course - NASH: From pathogenesis to non-invasive testing
    • Patient Resources
      • All Resources
      • ePosters
      • COVID-19 Resources
      • Infographics
      • Patient Guidelines
      • PDF
      • Podcasts
      • Slide Decks
      • Takeaways
      • Webcasts
  • EASL Studio
  • Journal Club

Patient Resources

This page is dedicated to educational resources for patients with liver disease.

Information message

In order to see all the search results and access content, you must log in. Please use the Log-in button at the top of the page.

Topics

  • Show all (4)
  • Liver Tumours (1)
  • Metabolism, Alcohol & Toxicity (2)
  • (-) Viral Hepatitis (1)

Patient Resource Type

  • Show all (17)
  • EASL Studio (3)
  • Clinical Practice Guidelines (1)
  • On-demand Webinars (1)
  • (-) Infographics (1)
  • PDF (11)

Congress and conferences

Language

  • (-) Show all (1)
  • English (1)

Year

  • (-) Show all (1)
  • 2020 (1)
Displaying results 1 - 1 of 1
Viral Hepatitis
Eliminating hepatitis C • Despite the ability of new direct-acting antiviral therapies to cure hepatitis C in almost all treated patients, HCV is still responsible for 400,000 deaths worldwide every year. Not only do patients face a number of barriers to treatment, but infection is largely asymptomatic until its later stages, leading to cirrhosis and liver cancer. To tackle the challenge of HCV, EASL is calling on all European countries to implement the WHO Global Health Sector Strategy on Viral Hepatitis action plan. EASL and the WHO believe that HCV can be eliminated as a public health threat by 2030, but we need to work together and take action now.














EASL.EU Home
Home of Hepatology
7 rue Daubin
1203 Geneva
Switzerland

Follow us:

Sign up to EASL News

©2019 - EASL. All Rights Reserved. Powered by Enovation.

Footer menu

  • Privacy Policy
  • Cookie Policy